May be useful in immunization/vaccination trials or may aid in the clinical diagnosis of diseases strongly associated with the HLA-DRB 3*, 4*, 5* loci.
- Patient Preparation
- Two 5 mL Lavender (EDTA). Also acceptable: One 10 mL Yellow (Solution A).
- Specimen Preparation
- Transport 5 mL whole blood. (Min: 3 mL)
- Storage/Transport Temperature
- Unacceptable Conditions
- Specimens collected in green (sodium or lithium heparin) tubes.
- Ambient: 1 week; Refrigerated: 1 week; Frozen: Unacceptable
Purpose: For immunization/vaccination trials or to aid the clinical diagnosis of diseases strongly associated with the HLA-DRB 3*,4*,5* loci.
Methodology: PCR followed by Sequence Specific Oligonucleotide Probe Hybridization of HLA-DRB 3*,4*,5* loci.
Analytical Sensitivity & Specificity: Medium to high resolution of HLA-DRB 3*,4*,5* loci.
Limitations: The presence of a disease-associated HLA combination does not establish a diagnosis. If fewer than 2 alleles are reported for a locus, the patient is likely homozygous. Rare diagnostic errors can occur due to primer or probe site mutations. This test is not sufficient for comprehensive HLA evaluation for clinical hematopoietic stem cell transplantation; for pre-transplant allele matching, consider HLA Class I (ABC) by Next Generation Sequencing (ARUP test code 2011264) and/or HLA Class II (DRB1 and DQB1) by Next Generation Sequencing (ARUP test code 2011272).
Occasionally the specific allele cannot be determined; in this case, the most likely allele assignment is made followed by a sequence of letters indicating other possible allele assignments. Interpretation of allele codes can be found at https://bioinformatics.bethematchclinical.org/hla/alpha.v3.html.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.
|Component Test Code*||Component Chart Name||LOINC|
Performed at UUHC - H&I Lab